BTC Speciality Health has amended its existing license and distribution agreement for itsBronchitol and Aridol respiratory medicine products, and extended its partnership with Arna Pharma.
The agreement was initially for 10 years, and has now been extended indefinitely.
In addition, Arna Pharma is building a pipeline of novel pharmaceutical products and has granted BTC the first right of refusal to commercialise them in the Australian and NZ markets.
The above article was sent to subscribers in Pharmacy Daily's issue from 11 Feb 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 11 Feb 25
